These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 36777569)
41. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice. Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307 [TBL] [Abstract][Full Text] [Related]
42. An energy-blocking nanoparticle decorated with anti-VEGF antibody to reverse chemotherapeutic drug resistance. Gu LQ; Cui PF; Xing L; He YJ; Chang X; Zhou TJ; Liu Y; Li L; Jiang HL RSC Adv; 2019 Apr; 9(21):12110-12123. PubMed ID: 35548379 [TBL] [Abstract][Full Text] [Related]
43. Novel virosecurinine bivalent mimetics as potent reversal agents against P-glycoprotein-mediated multidrug resistance. Hou W; Meng Y; Xu XF; Huang ZX; Liu J; Wang ZY; Lin J; Chen WM Eur J Med Chem; 2019 Dec; 183():111726. PubMed ID: 31585275 [TBL] [Abstract][Full Text] [Related]
44. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells. Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762 [TBL] [Abstract][Full Text] [Related]
45. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance. Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418 [TBL] [Abstract][Full Text] [Related]
46. Reversal of multidrug resistance of cancer through inhibition of P-glycoprotein by 5-bromotetrandrine. Jin J; Wang FP; Wei H; Liu G Cancer Chemother Pharmacol; 2005 Feb; 55(2):179-88. PubMed ID: 15378274 [TBL] [Abstract][Full Text] [Related]
47. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
48. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo. Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708 [TBL] [Abstract][Full Text] [Related]
49. Ascorbate promotes the cellular accumulation of doxorubicin and reverses the multidrug resistance in breast cancer cells by inducing ROS-dependent ATP depletion. Liu Y; Zhang L; Ma Z; Tian L; Liu Y; Liu Y; Chen Q; Li Y; Ma E Free Radic Res; 2019 Jul; 53(7):758-767. PubMed ID: 31170853 [TBL] [Abstract][Full Text] [Related]
50. Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells. Chakravarty G; Mathur A; Mallade P; Gerlach S; Willis J; Datta A; Srivastav S; Abdel-Mageed AB; Mondal D Biochimie; 2016 May; 124():53-64. PubMed ID: 26844637 [TBL] [Abstract][Full Text] [Related]
51. Rational Design of Multifunctional Polymeric Nanoparticles Based on Poly(l-histidine) and d-α-Vitamin E Succinate for Reversing Tumor Multidrug Resistance. Li Z; Chen Q; Qi Y; Liu Z; Hao T; Sun X; Qiao M; Ma X; Xu T; Zhao X; Yang C; Chen D Biomacromolecules; 2018 Jul; 19(7):2595-2609. PubMed ID: 29618203 [TBL] [Abstract][Full Text] [Related]
52. Jatrophane diterpenoids from Euphorbia sororia as potent modulators against P-glycoprotein-based multidrug resistance. Hu R; Gao J; Rozimamat R; Aisa HA Eur J Med Chem; 2018 Feb; 146():157-170. PubMed ID: 29407947 [TBL] [Abstract][Full Text] [Related]
53. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies. Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834 [TBL] [Abstract][Full Text] [Related]
54. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. Schneiderman RS; Shmueli E; Kirson ED; Palti Y BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723 [TBL] [Abstract][Full Text] [Related]
56. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model. Tiash S; Chowdhury EH J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549 [TBL] [Abstract][Full Text] [Related]
57. The anti-hepatitis drug DDB chemosensitizes multidrug resistant cancer cells in vitro and in vivo by inhibiting P-gp and enhancing apoptosis. Jin J; Sun H; Wei H; Liu G Invest New Drugs; 2007 Apr; 25(2):95-105. PubMed ID: 16937080 [TBL] [Abstract][Full Text] [Related]
58. Overcoming multidrug resistance via simultaneous delivery of cytostatic drug and P-glycoprotein inhibitor to cancer cells by HPMA copolymer conjugate. Sivak L; Subr V; Tomala J; Rihova B; Strohalm J; Etrych T; Kovar M Biomaterials; 2017 Jan; 115():65-80. PubMed ID: 27886555 [TBL] [Abstract][Full Text] [Related]
59. Design and synthesis of new potent N,N-bis(arylalkyl)piperazine derivatives as multidrug resistance (MDR) reversing agents. Dei S; Coronnello M; Bartolucci G; Manetti D; Romanelli MN; Udomtanakunchai C; Salerno M; Teodori E Eur J Med Chem; 2018 Mar; 147():7-20. PubMed ID: 29421572 [TBL] [Abstract][Full Text] [Related]
60. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo. Xu HB; Shen ZL; Fu J; Xu LZ Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]